KRAS and cancer: In this context, LAT1 is required for efficient growth of KRAS-mutant colorectal cancer, and rapamycin reduces LAT1-deficient cell proliferation and tumor formation [47], suggesting LAT1 as an attractive therapeutic target for various cancers.